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t(8;21) is one of the most frequent chromosomal abnormalities observed in patients 
with acute myeloid leukemia (AML).  However, expression of AML1-ETO is not 
sufficient to induce transformation in vivo.  Consistent with this observation, patients 
with this translocation harbor additional genetic abnormalities, suggesting a 
requirement for cooperating mutations.  To better define the genetic landscape in 
AML and distinguish driver from passenger mutations, we compared the mutational 
profiles of AML1-ETO driven mouse models of leukemia to the mutational profiles of 
human AML patients.  We identified TET2 and PTPN11 mutations in both mouse and 
human AML and then demonstrated the ability of Tet2 loss and PTPN11 D61Y to 
initiate leukemogenesis in concert with expression of AML1-ETO in vivo.  This 
integrative genetic profiling approach allowed us to accurately predict cooperating 
events in t(8;21)+ AML in a robust and unbiased manner, while also revealing 
functional convergence in mouse and human AML. 
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The translocation between chromosomes 8 and 21 creates a fusion protein known 
as AML1-ETO, which has been proven insufficient for leukemogenesis.  The goal 
of this study was to identify disease alleles capable of cooperating with AML1-
ETO to initiate leukemia in vivo using the genomics of both mouse and human 
AML.  In seeking to identify cooperating alleles, Megan generated two novel 
mouse models of t(8;21) driven Acute Myeloid Leukemia.  These models provide 
information on the requirements for AML1-ETO leukemogenesis, and can be 
used to determine if targeted therapeutics against either disease allele would be 
beneficial. 
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1 
INTRODUCTION 
 
Hematopoiesis 
 
Hematopoiesis is a complex process by which an immature cell, capable of generating 
identical daughter cells, gives rise to mature progeny each capable of executing a 
specific function within the blood and bone marrow compartment.  The hierarchical 
nature of this process was first postulated by biologist A. Maximow1, but could not be 
substantiated until later studies pioneered the use of bone marrow transplantation.  
During the atomic era, transplantation of bone marrow or spleen cells from a healthy 
individual into one exposed to radiation was found to preclude lethal bone marrow 
failure2.  This finding supported the existence of cells capable of reconstituting the 
hematopoietic system but could not determine whether mature cells originated from a 
single immature cell or multiple immature cells, each responsible for a specific blood 
lineage.  Seminal studies in mice which demonstrated that multiple blood lineages 
could be reconstituted from the cells that formed macroscopic colonies in the spleen 
after transplantation provided the evidence required for attributing all mature cells to a 
single immature cell3,4, referred to as a hematopoietic stem cell.  Scientists have since 
refined the morphological features and cell surface proteins that characterize stem 
cells, subsequent progenitor cells, and various mature cells, organizing the 
heterogeneous blood and bone marrow compartment into one in which cellular 
identity and potential is defined.      
 
It is understandable that a complex process of cellular maturation be regulated in a 
similarly complex manner.  However, the process of maturation, known as 
differentiation, can best be described at the cellular level for a hematopoietic stem or 
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progenitor cell as a decision to generate either two identical daughter cells, an 
identical daughter cell and a more differentiated daughter cell, or two differentiated 
daughter cells.  This cell fate decision has been described in probabilistic terms5, and 
has largely been attributed to changes in the expression of a variety of genes at 
specific time points.  Changes in gene expression, in turn, are regulated by a plethora 
of factors, including the expression of transcription factors6, epigenetic factors7,8, RNA 
machinery9, and the initiation of cytokine signaling cascades10. 
 
One gene critical to hematopoiesis is AML1 (also known as RUNX1).  AML1 itself is 
a transcription factor that, owing to alternative splicing, can possess varying amounts 
of C-terminal transcript and, as a result of alternative promoter usage, can express an 
extended N-terminal transcript11,12.  Conserved in the majority of AML1 isoforms is a 
runt homology domain that allows AML1 to bind DNA at a specific consensus 
sequence13 and regulate the expression of genes relevant to differentiation.  It is 
important to note that while AML1 has been found to activate the expression of 
cytokines such as IL314 and GM-CSF15, and factors important to granulopoiesis, such 
as myeloperoxidase16, MCSF receptor17, and neutrophil elastase18, AML1 itself is a 
weak activator and typically achieves gene regulation via the recruitment of different 
co-activators, including MEF19, C/EBPα, PU.117, CBP/p30020, and c-MYB21, to 
different target genes.  In this manner, AML1 is capable of acting broadly, altering the 
expression of a wide variety of hematopoietic genes, gene regulators, and signaling 
pathways.  Mice null for AML1 die at an early embryonic stage, experiencing a 
complete block in definitive hematopoiesis.  Only yolk-sac derived primitive 
hematopoiesis remains intact22,23.  The fact that a single transcription factor could have 
such a lethal effect underscores the importance not only of hematopoiesis, but of its 
regulation.   
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Acute Myeloid Leukemia 
 
The loss, disruption, or mutation of genes relevant to hematopoiesis can have lethal 
effects, and that lethality at times results from the development of leukemia.  
Leukemia is defined as the clonal expansion of immature hematopoietic cells with 
impaired differentiation potential.  Accordingly, two biological features have become 
hallmarks of a leukemic state: continuous proliferation and concurrent differentiation 
arrest24.    
 
Acute myeloid leukemia (AML) is subtype of leukemia in which the malignant stem 
or progenitor cell is one that would not have contributed to the development of 
lymphocytic cells, but instead would have contributed to the development of cells 
belonging to the myeloid lineage.  The annual incidence of AML is approximately 2.4 
in 100,000 in the United States25, and this rate increases more than 5 fold for 
individuals older than 65.  Despite having a lower incidence rate, individuals younger 
than 65 still face a survival rate of only 40%26.  The majority of AML patients present 
with cytogenetic abnormalities27,28, and their resulting karyotype is an independent 
predictor of overall survival.  Of note, balanced chromosomal translocations are 
common in AML, and the translocation breakpoint occurs at genes that are almost 
always transcription factors.  In several cases, a chimeric fusion protein is generated 
via the expression of two different genes at either side of the breakpoint.  This fusion 
protein can interfere with the functions of either affected gene or assume novel 
functions itself24.  The predominance of chromosomal aberrations in AML and their 
impact on patient survival has prompted investigations into the mechanisms by which 
the affected genes may contribute to malignant cell proliferation or differentiation 
arrest. 
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Two-Hit Hypothesis 
 
While a hallmark of acute myeloid leukemia is the targeting of transcription factors by 
chromosomal aberrations, the chromosomal translocations present in chronic myeloid 
leukemia (CML) overwhelmingly target tyrosine kinases.  In the majority of these 
translocations, a fusion protein is generated that harbors not only a tyrosine kinase 
domain, but an oligomerization motif which facilitates the constitutive activation of 
the respective kinase.  When expressed in hematopoietic cell lines, the fusion protein 
is capable of activating cytokine signaling cascades such that cellular growth is 
possible in the absence of cytokines.  When expressed in animal models, the fusion 
protein consistently induces a myeloproliferative neoplasm (MPN), a disorder 
characterized by the accumulation of a single mature cell type29. 
 
The expression of transcription factor fusion proteins in AML does not promote 
cytokine independent cell growth; instead, the primary consequence is an impairment 
in differentiation.  This impairment in part can result from the loss-of-function of one 
or both genes involved in the translocation.  For example, expression of the t(8;21) 
fusion product, AML1-ETO, results in embryonic lethality and a block in definitive 
hematopoiesis30,31, a phenotype reminiscent of AML1 loss.  Notably, transcription 
factor fusion proteins present in AML rarely induce overt leukemia when expressed 
alone.  Conditional expression of AML1-ETO in murine models is capable of inducing 
leukemia only after mutagenic agents like N-ethyl-N-nitrosourea have been 
employed32,33.  Fusion proteins such as CBFβ-SMMHC and PML-RARα, induce 
leukemia with incomplete penetrance after an extensive latency34,35.  These results 
suggest a requirement for secondary genetic events in leukemias characterized by 
transcription factor fusion proteins. 
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Such a requirement has been substantiated by studies of CML and MPNs and their 
progression to AML.  In a select number of cases, a secondary genetic event not 
identified in the initial diagnosis is discovered in the resultant AML.  For instance, 
patients with BCR-ABL positive CML have been found to acquire t(7;11), a 
translocation which results in expression of the NUP98-HOXA9 fusion protein, during 
blast crisis36,37.  Similarly, a patient presenting with the MPN known as Polycythemia 
vera, and harboring the JAK2 V617F mutation has been found to progress to AML 
after acquiring AML1-ETO38.  These observations not only support the co-occurrence 
of secondary events with transcription factor fusion proteins, but also suggest a model 
of AML that is reliant upon the acquisition of two classes of mutations.  The first class 
of mutations (Class I) is typified by those present in CML and MPNs; the mutations 
confer a proliferative advantage to cells, without affecting their ability to differentiate.  
The second class of mutations (Class II) is typified by transcription factor fusion 
proteins, which impair differentiation but do not provide a proliferative advantage29.  
A cell that has acquired mutations in both classes is capable of the clonal outgrowth 
which defines AML.  This model of leukemogenesis is now known as the two-hit 
hypothesis.   
 
AML1-ETO* 
 
AML1-ETO is an exemplary Class II mutation.  And while the translocation between 
chromosomes 8 and 21 was first identified in AML by Dr. Janet Rowley more than 
four decades ago39, investigators have only recently begun to understand the functions 
of AML1-ETO and its role in leukemogenesis.  Clinically, the t(8;21) translocation 
                                                          
* Hatlen MA and Nimer SD. AML1-ETO driven acute leukemia: insights into pathogenesis and 
potential therapeutic approaches. Frontiers of Medicine. 6, 248-262 (2012). 
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represents the most frequent chromosomal abnormality in AML, occurring in 
approximately 4%–12% of adult and 12%–30% of pediatric patients40.  t(8;21)+ 
leukemias exhibit some degree of myeloid differentiation, which has led to their 
classification as a M2 subtype of AML, based on the French-American-British (FAB) 
Working Group Classification system41,42.  Several groups identified the AML1 gene 
on chromosome 21 as being fused to the ETO gene on chromosome 8, and as a result 
of this work the AML1-ETO fusion cDNA was ultimately cloned.  AML1-ETO 
contains the RUNT homology domain of AML1 and nearly the full length open 
reading frame of the ETO gene43,44,45,46,47,48.   
 
While the N-terminal component of the AML1-ETO fusion protein, AML1, is a 
transcription factor that regulates the expression of a variety of genes related to 
myeloid and lymphoid differentiation, the role of the C-terminal component of AML1-
ETO, ETO (also known as MTG8), in hematopoiesis is less well defined.  There is no 
expression of murine ETO in early mouse hematopoietic cells, and mice lacking ETO 
have no obvious defects in hematopoiesis; their primary phenotype is a reduction in 
postnatal viability and impaired midgut formation49.  It is generally believed that ETO 
and its family members ETO-2/MTG16 and MTGR1 act in transcriptional silencing, 
as they bind corepressors such as nuclear receptor corepressor (NCoR), silencing 
mediator for retinoid/thyroid hormone receptors (SMRT), mSin3a, and various 
members of the histone deacetylase (HDAC) family via four evolutionarily conserved 
nervy homology regions (NHR)50,51,52.  These domains are retained in the AML1-ETO 
fusion protein, along with the DNA binding domain of AML1.  Initial studies of 
AML1-ETO identified it as a dominant inhibitor of AML1 function53,54, and were 
supported by the knock-in mouse model of AML1-ETO, which largely replicates the  
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phenotype of AML1 null mice (Table 1).  However, while the AML1 null fetal liver 
lacks hematopoietic stem/progenitor cells (HSPCs), the fetal livers of AML1-ETO                                                                                                                                  
                                                                                                                               
Table 1.  Mouse Models of AML1-ETO Expression 
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knock-in mice contain small numbers of multilineage progenitor cells with dysplastic 
morphology, which possess increased self-renewal capacity when cultured in vitro30,31.  
These results allude to functions of AML1-ETO that are distinct from its ability to 
block AML1 function, and that are likely also critical to leukemogenesis. 
 
Transgenic Expression of AML1-ETO 
Efforts to establish mouse models of t(8;21)+ AML, and bypass the embryonic 
lethality of AML1-ETO “knock-in” expression, led to the generation of several mouse 
models where AML1-ETO was conditionally expressed (Table 1).  An elegant model, 
in which the translocation between the murine AML1 and ETO genes was induced via 
CRE/LoxP mediated recombination, showed no leukemia when CRE was expressed 
from the Nestin promoter.  However, the use of the Nestin promoter to induce 
recombination in this model was not ideal, as it generated the translocation in brain, 
kidney, and heart tissues, but not in bone marrow cells55.  The Zhang laboratory 
subsequently generated a transgenic mouse in which the expression of AML1-ETO 
was under the control of a tetracycline-responsive element.  In the absence of 
tetracycline, the AML1-ETO protein was detectably expressed in bone marrow cells, 
and although the animals did not develop leukemia, the bone marrow cells expressing 
AML1-ETO did show increased self-renewal and a partial block in myeloid 
differentiation33.   
 
A similar phenotype was seen with a conditional AML1-ETO knock-in mouse model.  
By placing a transcriptional stop cassette flanked by LoxP sites in the third intron of 
AML1, and inserting the remaining AML1-ETO cDNA in frame to exon 4, the 
Downing laboratory created an AML1-ETO allele that could be expressed from the 
endogenous AML1 promoter following CRE/LoxP mediated recombination32. When 
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these mice were crossed with Mx1-Cre+/- mice56, and poly(I:C) treatment was used to 
delete the stop cassette, AML1-ETO expression occurred in the hematopoietic 
compartment.  AML1-ETO increased the self renewal of the bone marrow cells 
without impairing their ability to form colonies in methylcellulose cultures, although 
there was a slight skewing toward the granulocyte/macrophage lineage.  Importantly, 
AML1-ETO expression did not initiate leukemia in this knock-in model32. 
 
To induce acute leukemia in this conditional knock-in model, the AML1-ETO-Stop/+; 
Mx1-Cre+/-  mice were treated first with poly(I:C) and then N-ethyl-N-nitrosourea 
(ENU) to generate additional genetic events.  Nearly half of these mice developed 
hematopoietic neoplasms, which were largely granulocytic sarcoma/acute myeloid 
leukemia, with features reminiscent of t(8;21)+ AML.  The remaining neoplasms were 
thymic-derived T cell lymphoblastic lymphomas that did not express AML1-ETO32.  
A similar result was seen when ENU was administered to transgenic mice in which 
AML1-ETO was expressed under the human MRP8 promoter; approximately half of 
the treated mice succumbed to AML while the remaining mice succumbed to 
lymphoma or acute lymphocytic leukemia (ALL).  These MRP8-AML1-ETO 
transgenic mice did not develop disease without ENU treatment57, and the occurrence 
of lymphoma or ALL in the ENU treated mice is not surprising, as ENU induces 
lymphomas or ALL in wildtype mice58.   
 
Taken together, these models clearly show that AML1-ETO expression alone is 
insufficient for leukemia initiation.  Ultimately, the increase in self-renewal that 
AML1-ETO provides must be supplemented with additional genetic or epigenetic 
events to initiate leukemia.  This is compatible with the in utero detection of the 
t(8;21) AML1-ETO translocation in children who develop AML later in life, even 
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more than 10 years after birth59.  It is also supported by the detection of  additional 
genetic abnormalities in t(8;21)+ AML patients at diagnosis, such as the loss of a sex 
chromosome, chromosomal deletions or trisomies, and mutations in receptor tyrosine 
kinases60.  In fact, although they did not report on AML1-ETO positive AML 
specifically, data emerging from the whole genome sequencing efforts of the 
Washington University group on primary human AML patient samples have 
demonstrated that the "average" AML likely contains dozens of mutations61,62. 
 
Mouse Models of AML1-ETO Driven Leukemogenesis 
To better understand which secondary events can cooperate with AML1-ETO to 
induce leukemia, investigators have taken advantage of retroviral transduction and 
transplantation experiments in mice, introducing AML1-ETO together with a variety 
of cDNAs.  When bone marrow Lin-Sca-1+c-Kit+ (LSK) cells, a population highly 
enriched for HSPCs, are transduced with AML1-ETO expressing retrovirus alone, and 
transplanted into lethally irradiated congenic recipient mice, the mice do not develop 
leukemia.  Instead, AML1-ETO positive myeloblasts are found in the bone marrow of 
recipient mice 10 months post-transplantation, and these cells, which may represent 
10% of the bone marrow population, show increased self-renewal in colony forming 
assays63.  However, when bone marrow cells are transduced with AML1-ETO and 
either the TEL-PDGFβR fusion protein64, the FLT3 length mutation (FLT3-LM)65, or 
the c-KIT N822K mutation66, recipient mice succumb to fatal AML with a median 
latency of 60, 233, or 178 days, respectively.  Of these secondary events, the c-KIT 
mutation is the most commonly identified mutation in t(8;21)+ leukemia patients.  At 
euthanasia, the leukemic mice in each of these transplant models show leukocytosis, 
anemia, thrombocytopenia, splenomegaly, and a blast population that exceeds 20% of 
the bone marrow cells.  These leukemias require the DNA binding ability of AML1-
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ETO64,65,66 and they are transplantable into sub-lethally irradiated recipient mice.  For 
instance, when TEL-PDGFβR is paired with an AML1-ETO L148D mutant that lacks 
the ability to bind DNA (or interact with CBFβ), the recipient mice develop a MPN 
similar to that seen from TEL-PDGFβR expression alone64.  FLT3-LM and c-KIT 
N822K also give rise to a MPN when expressed individually67.   
 
Because these mutations result in the constitutive activation of a tyrosine kinase that 
confers a proliferative advantage to hematopoietic cells, they are each considered a 
Class I mutation68,69.  The ability of AML1-ETO to cooperate with three different 
Class I mutations lends validity to the two-hit hypothesis; however, as more mutations 
are identified in AML patients, events capable of cooperating with AML1-ETO have 
been discovered that do not necessarily comply with the requirements of a Class I 
mutation.  This suggests that while the two-hit hypothesis is clearly biologically 
applicable to AML, as mutations of a given class generally do not co-occur in patients, 
it may represent an oversimplification of AML.   
 
One event that does not fulfill the tenets of a Class I mutation, yet cooperates with 
AML1-ETO, is the overexpression of transcription factor WT1.  WT1 is upregulated 
in AML patients70, and although originally described as a tumor suppressor gene, the 
overexpression of WT1 has been found to not only promote the proliferation of mouse 
bone marrow progenitor cells, but to also inhibit their differentiation in response to G-
CSF71.  Mice transplanted with bone marrow cells from WT1 overexpressing 
transgenic (WT1-Tg) mice have splenomegaly and an increased number of mature 
myeloid cells and myeloid progenitor cells in the bone marrow; however, they do not 
develop AML.  When AML1-ETO is expressed in WT1-Tg bone marrow cells, the 
recipient mice die of an aggressive, invasive AML 1 to 4 months post-transplant72.  
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In a similar scenario, AML1-ETO cooperates with the loss of interferon consensus 
sequence binding protein (ICSBP, also known as interferon regulatory factor 8) to 
induce myeloblast transformation in mice.  ICSBP expression is downregulated in 
AML patient samples, which prompted experiments expressing AML1-ETO in 
ICSBP-/- mouse bone marrow cells.  While the transplantation of ICSBP-/- bone 
marrow cells leads to a MPN, the expression of AML1-ETO in these cells leads to an 
accumulation of myeloblasts in the bone marrow of the recipient mice and non-fatal 
granulocytic sarcomas73.  Though not AML, the development of this latter 
pathological feature, which is present in some t(8;21)+ AML patients74, is suggestive 
of ICSBP loss playing an important role in disease progression to overt AML.   
 
It may in fact be possible for AML to result from an accumulation of multiple 
functional hits, just as it is possible for AML to result from the acquisition of two 
classical hits.  Through studies in myeloid cell lines, the Zhang laboratory found that 
AML1-ETO could trigger growth arrest by binding to the p21 promoter and inducing 
its expression75.  They hypothesized that growth arrest and p21 upregulation must be 
circumvented for AML1-ETO to be fully leukemogenic, possibly through the actions 
of a cooperating hit.  Accordingly, when AML1-ETO was expressed in p21-/- mouse 
fetal liver cells, many of the recipient mice developed a lethal AML after a latency of 
at least 4 months. The extensive latency, the fact that the p21 gene is rarely inactivated 
in patients with AML76,77,78,79, and the fact that t(8;21)+ AML patient samples 
generally overexpress p2180, makes it unlikely that the loss of p21 directly synergized 
with AML1-ETO expression in this mouse model of AML.  Instead, this model 
appears to demonstrate the importance of certain p21 regulated processes in AML1-
ETO driven leukemogenesis. p21 plays a role in DNA damage repair81,82,83, and its 
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loss could result in the accumulation of mutations and/or epigenetic events that 
contribute to leukemogenesis in the presence of AML1-ETO.  In this scenario, at least 
two genetic events, p21 loss and an acquired mutation, cooperate with AML1-ETO.   
 
Aside from cooperativity studies, our understanding of the leukemogenic potential of 
AML1-ETO has been significantly advanced by the identification of an AML1-ETO 
splice variant, AML1-ETO9a, which can induce AML after a 5-6 month latency.  In 
2004, the Zhang laboratory transplanted mouse bone marrow cells that had been 
retrovirally transduced with AML1-ETO into recipient mice.  One of the recipient 
mice developed AML 14 weeks post-transplantation without any artificially induced 
mutations.  Sequencing of the AML1-ETO cDNA in the leukemic cells revealed a 
single base-pair insertion that resulted in a C-terminal truncation of approximately 180 
amino acids, eliminating the NHR3 and NHR4 domains84.  Using the point of 
truncation as a reference, the Zhang laboratory identified an alternatively spliced 
transcript of AML1-ETO in cells where the ETO portion of the fusion mRNA 
included a 155 base-pair exon (9a).  The inclusion of exon 9a changes the reading 
frame of ETO and introduces a premature stop codon85, thereby generating a truncated 
AML1-ETO protein that lacks the NHR3 and NHR4 domains. The AML1-ETO9a 
(AE9a) transcript is only ~20 base pairs longer than the truncated AML1-ETO cDNA 
that was found in the one mouse that developed AML.  When cells are co-transduced 
with AE9a and AML1-ETO, leukemia occurs more rapidly than when AE9a is 
expressed alone. The identification of this AML1-ETO isoform was made more 
relevant by its detection in t(8;21)+ AML patients; in one report, 27 of 37 patient 
samples were found to contain AE9a RNA86.  The presence of AE9a RNA appears to 
correlate with the presence of c-KIT mutations and a worse overall survival87.  
However, studies of AML1-ETO protein expression in AML have not identified a C-
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terminally truncated protein of the correct size; the overwhelmingly detectable isoform 
of AML1-ETO is the full-length 94 kDa protein.  At present, our understanding of 
why this truncated form of AML1-ETO induces leukemia, while its full length 
counterpart does not, is minimal.  
 
Therapeutic Approaches for t(8;21) Positive AML 
Treatment for t(8;21)+ AML patients typically begins with induction chemotherapy, 
which for decades has been the combination of cytarabine for seven days, together 
with three daily doses of an anthracycline (daunorubicin or idarubicin). If a complete 
remission is achieved, consolidation chemotherapy is given, which for t(8;21)+ AML 
consists of multiple courses of high dose cytarabine88,89.  Although AML patients 
harboring the t(8;21) translocation are generally given a good prognosis and the 
majority achieve complete remission, the 5-year survival is only ~50%, and the 
presence of a c-kit mutation decreases the prognosis significantly27. Several avenues 
of treatment are currently being explored, and they include targeting aberrant 
microRNA and gene expression, as well as repurposing inhibitors for use in t(8;21)+ 
AML.  
 
MicroRNAs are now recognized as fundamental components of gene regulation90, 
contributing to the coordinate regulation of many developmental programs via effects 
on mRNA degradation and translation91,92,93.  Given the variety of effects that AML1-
ETO has on differentiation, self-renewal, and apoptosis, it is not surprising that several 
hematopoiesis-related microRNAs have been found to be direct AML1-ETO targets. 
The Nervi and Beghini laboratories have shown that miR-223 and miR-222/221 are 
downregulated in t(8;21)+ leukemic blasts, compared to normal bone marrow 
cells94,95.  These microRNAs are expressed at low levels in primitive hematopoietic 
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cells, and they increase in abundance with differentiation along the granulocytic 
lineage96.  By binding to an AML1 consensus binding site located 5′ of the pre-miR-
223 gene, AML1-ETO silences miR-223 expression and impairs differentiation. 
Treating AML1-ETO positive SKNO-1 cells with the DNA methyltransferase 
inhibitor 5-azacytidine, or knocking down AML1-ETO expression with shRNA 
restores miR-223 expression and induces granulocytic maturation94. 
 
miR-222/221 is also directly repressed by the binding of AML1-ETO to an upstream 
AML1 consensus binding site95.  Interestingly, while miR223 regulates differentiation 
via interactions with C/EBPα or NFI-A96, miR-222/221 appears to regulate 
differentiation by targeting the 3′ untranslated region (UTR) of c-KIT mRNA97.  The 
downregulation of miR-222/221 by AML1-ETO correlates with heightened c-KIT 
expression, providing a mechanism for the overexpression of wild type c-KIT in 
t(8;21)+ leukemia. 
 
A mechanistic link between t(8;21)+ AML and mitogen-activated protein kinase 
(MAPK) signaling is provided by miR-24 overexpression. While miR-223 and miR-
222/221 are repressed by AML1-ETO, AML1-ETO appears to activate miR-24 
expression98. miR-24 targets the 3′ UTR of MKP-7 (a.k.a. dual-specificity phosphatase 
16), lowering its expression and thereby promoting MAPK signaling via decreased 
dephosphorylation99. When miR-24 expression increases, proliferation is accelerated 
and granulocytic differentiation is blocked, which can contribute to the t(8;21) 
leukemic phenotype. 
 
Other microRNAs may play a role in t(8;21)+ acute leukemia without being direct 
transcriptional targets of AML1-ETO.  For instance, in a genome-wide, miRNA 
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expression analysis of 47 primary AML samples, miR-126 was found to be 
specifically overexpressed in the 10 t(8;21)+ AML samples, possibly as a result of 
decreased methylation within a CpG island that controls its expression. Forced 
expression of miR-126 in mouse bone marrow cells leads to increased proliferation 
and enhanced serial replating ability; these effects are amplified by the co-expression 
of AML1-ETO100. Determining whether the deregulation of miR-126, or other 
microRNAs, is a cause or consequence of AML1-ETO positive leukemias should help 
determine whether targeting specific microRNAs would be useful therapeutically. 
 
Just as microRNAs are deregulated in t(8;21)+ AML, so has the deregulation of gene 
expression become a hallmark of the disease.  In fact, unsupervised clustering of 
microarray data has allowed for the identification of leukemia subgroups, such as 
t(8;21)+ AML and CBFβ rearranged [inv(16) and t(16;16)] AML, based solely upon 
distinct gene expression signatures101,102.  Many investigators have focused on the 
mechanisms underlying the repression of AML1-ETO target genes, however, many 
AML1-ETO target genes are upregulated following expression of AML1-ETO in 
U937 cells and human CD34+ cells.  The relative importance of upregulated versus 
downregulated genes in the pathogenesis of AML1-ETO driven AML remains to be 
determined because these genes have generally been evaluated one at a time, an 
approach that is slow and painstaking. One gene, the groucho-related N-terminal 
enhancer of split (AES), has been identified as being consistently upregulated in 
t(8;21)+ AML103,104.  Its functional importance was shown when AES knock-down in 
a t(8;21)+ cell line, Kasumi-1, and in AML1-ETO transduced mouse bone marrow 
cells decreased colony formation and methylcellulose replating ability.  The self-
renewal promoting effects of AES may reflect increased WNT signaling, which would 
be consistent with the upregulation of survivin that has also been found in t(8;21)+ 
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AML patient samples105.  Survivin is an inhibitor of apoptosis and a target of 
canonical WNT signaling; its expression is directly induced by the binding of AML1-
ETO to the survivin promoter.  Similar to the effects of AES knock-down, knock-
down of survivin impairs the growth of AML1-ETO expressing cells, and promotes 
their granulocytic differentiation106.  The therapeutic targeting of survivin is being 
explored in a variety of cancers107,108 and hopefully one day will be explored in 
t(8;21)+ AML. 
 
Like WNT signaling, RAS signaling has also been implicated in promoting AML1-
ETO driven acute leukemia.  Ras overexpression, or mutations in N-RAS that lead to 
its constitutive activation, are among the most frequent abnormalities found in 
t(8;21)+ AML109,110, and the transduction of activated N-RAS G12D into AML1-ETO 
expressing human CD34+ cells results in their transformation to cytokine 
independence with increased colony formation and replating ability. These cells also 
engraft better than AML1-ETO singly expressing cells in immunodeficient mice [both 
NOD/SCID/IL2rγ-/- (NSG) mice and NOD/SCID mice transgenic for stem cell factor, 
granulocyte-macrophage colony-stimulating factor, and interleukin-3 (NSS)]. 
However, mice that are xenotransplanted with these CD34+ cells do not develop acute 
leukemia111. 
 
The BCL2 promoter is transcriptionally activated by AML1-ETO in leukemia cell 
lines112.  This activation may be a signature of more fully transformed cells because 
while BCL2 is overexpressed in AML1-ETO and N-RAS G12D coexpressing CD34+ 
cells, it is not overexpressed in AML1-ETO singly expressing CD34+ cells.  BCL2 is 
potentially a clinically relevant target for the treatment of AML1-ETO and N-RAS 
G12D coexpressing CD34+ cells, as ABT-737, an inhibitor of BCL-2 family 
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members, decreased their in vitro growth111.  Though co-expression of BCL-2 with 
AML1-ETO does not recapitulate all of the leukemic features of N-RAS G12D and 
AML1-ETO co-expression, this sensitivity to ABT-737 suggests that BCL2 activation 
may play a role in the progressive transformation of AML1-ETO expressing cells, and 
could be an important therapeutic target for t(8;21)+ AML. 
 
Other BCL-2 family members, in particular BCL-XL, may also be clinically relevant 
to t(8;21)+ AML.  The expression of AML1-ETO in CD34+ cells activates signaling 
through the thrombopoietin (THPO)/MPL pathway, which upregulates BCL-XL 
expression.  Knockdown of BCL-XL in these cells induced apoptosis, decreased in 
vitro colony formation, and impaired engraftment in NSG mice, while the 
overexpression of BCL-XL in these cells enhanced their serial replating ability and 
LTC-IC frequency.  MPL/BCL-XL signaling appears to be upregulated in t(8;21)+ 
AML patient samples compared to leukemic blasts isolated from AML patients with 
normal cytogenetics.  Targeting the THPO/MPL/BCL-XL signaling axis may be 
another viable therapeutic option for t(8;21)+ AML patients, as withdrawal of THPO 
from AML1-ETO expressing CD34+ cultures decreased BCL-XL expression, 
impaired cell growth, and increased apoptosis. Similar effects were not seen after 
withdrawal of stem cell factor (SCF) or Fms-like tyrosine kinase 3 ligand (FLT3L)113. 
 
Chemical inhibitors targeting t(8;21)+ AML have frequently been directed against 
those key proteins or pathways that are required for AML1-ETO function (Table 2). 
One protein, calpain B, was identified based on an RNA-interference (RNAi) screen in 
Drosophila and shown to be required for the effects of AML1-ETO on Drosophila 
blood cell numbers and differentiation capability.  Encouragingly, treatment of 
Kasumi-1 cells with calpain inhibitors, such as N-acetyl-leucyl-leucyl-  
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Table 2.  Inhibitors with Therapeutic Potential for t(8;21)+ AML  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
norleucinal (ALLN) and calpain inhibitor III, led to the degradation of AML1-ETO 
and a decrease in cell viability.  In contrast, Calpain inhibitors had no effect on HL-60                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
cells or pediatric acute lymphoblastic leukemia patient samples114.  Calpains represent 
a large family of Ca2+-dependent cysteine proteases; however, their role in 
hematopoiesis is not well understood.           
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In a high throughput screen, Kasumi-1 cells were treated with a total of 2,480 different 
FDA-approved drug compounds, with promising compounds being identified as "hits" 
if they could recapitulate the 28 gene-member expression profile indicating "AML1-
ETO abrogation."  These hits fell primarily within two drug classes: corticosteroids 
and dihydrofolate reductase (DHFR) inhibitors, with methylprednisolone and 
methotrexate chosen to represent each class.  Treatment with either drug reduced 
colony formation by Kasumi-1 cells, and induced myeloid differentiation and 
apoptosis.  Methylprednisolone has been shown to specifically trigger apoptosis in 
AML1-ETO harboring cell lines, and to synergize with the traditional AML therapies, 
cytosine arabinoside (Ara-C) and daunorubicin115.  Interestingly, a t(8;21)+ AML 
patient who received a short course of high-dose methylprednisolone for pneumonia 
had clearance of AML1-ETO positive leukemia cells116.  Methotrexate appears to be 
less specific for AML1-ETO positive cells, and it did not synergize with Ara-C and 
daunorubicin in vitro.  However, it did reduce leukemia cell burden in NOG mice 
transplanted with t(8;21)+ SKNO-1 cells115. 
 
A separate screen for chemical inhibitors of AML1-ETO function utilized transgenic 
zebra fish embryos heterozygous for AML1-ETO, which display hematopoietic 
features reminiscent of human t(8;21)+ AML [i.e. downregulation of GATA1 and 
SCL, and upregulation of myeloperoxidase (MPO)].  Transgenic embryos were 
incubated with 2,000 bioactive compounds, and the compounds were flagged as hits if 
at least 4 of the 5 embryos stained strongly for GATA1 expression.  Of the 2,000 
tested compounds, both nimesulide and dicumarol were able to restore GATA1 
expression without altering AML1-ETO expression.  Nimesulide is a known 
cyclooxygenase-2 (COX-2) inhibitor, and treatment of transgenic embryos with a 
similar inhibitor, NS-398, also triggered GATA1 upregulation.  Investigations into the 
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COX-2 pathway revealed that AML1-ETO upregulates COX-2 expression, and may 
require it and prostaglandin E2 (PGE2), a cyclooxygenase metabolite, for its effects on 
hematopoietic cells.  PGE2 has been shown to promote the proliferation of various 
tumor cells by activating β-catenin-dependent signaling.  Indeed, knockdown of either 
β-catenin-1 or β-catenin-2 in transgenic embryos was able to restore GATA1 
expression.  Consistent with this effect, AML1-ETO significantly increased the 
expression of COX-2 in human K562 cells, and treatment with NS-398 removed the 
AML1-ETO driven block in erythroid differentiation117.  The importance of COX/β-
catenin signaling remains to be investigated in AML1-ETO mouse models and in 
primary cells isolated from t(8;21)+ AML patients.   
 
In contrast to performing large scale screens to identify novel AML1-ETO inhibitors, 
some investigators have focused on using traditional Chinese herbs to treat t(8;21)+ 
AML118, such as Eriocalyxin B (EriB), an entkaurene diterpene compound isolated 
from an herb of the Labiatae family, Isodon eriocalyx var. laxiflora.  EriB 
treatment preferentially triggers the apoptosis of AML1-ETO expressing cells, 
possibly through the deregulation of MAPK signaling.  EriB showed efficacy on 
five t(8;21)+ AML patients and two different mouse models of t(8;21)+ AML: C57 
mice transplanted with cells expressing the C-terminally truncated AML1-ETO 
showed increased survival if treated with EriB (32 days for EriB at 2.5 mg/kg, 
compared to 25 days for control treated mice).  EriB also reduced the size of 
subcutaneous Kasumi-1 cell tumors in a xenograft nude mouse model119.  How EriB 
preferentially exerts its anti-leukemic abilities on AML1-ETO positive leukemia cells 
is unknown. 
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Another compound, Triptolide, purified from the Chinese herb Tripterygium wilfordii, 
also has anti-proliferative effects on SKNO-1, Kasumi-1, and t(8;21)+ AML patient 
cells, without significantly affecting normal blood cell growth.  Triptolide may act by 
reducing the levels of c-KIT and NF-κB related p65, and by impairing JAK/STAT 
signaling120.  These pathways are activated in AML1-ETO positive leukemia cells121, 
which may explain the antileukemic effects of Triptolide.  
 
Bortezomib, a proteasome inhibitor, appears to target leukemia cells with activated c-
KIT.  It blocked the proliferation and induced the apoptosis of Kasumi-1 and SKNO-1 
cells, as well as CD34+ cells isolated from t(8;21)+ AML patients. Exposure to 
bortezomib triggered the internalization and lysosomal degradation of c-KIT.  Both 
wildtype c-KIT and the constitutively active c-KIT mutant, N822K, phosphorylate 
HSP90β, which enhances the binding of HSP90β to apoptotic protease activating 
factor 1 (APAF-1).  By inducing the degradation of c-KIT, Bortezomib indirectly 
decreased HSP90β phosphorylation, triggering the release of APAF-1 which leads to 
activation of caspase 3. Interestingly, caspase 3 is capable of cleaving AML1-ETO 
and AML1-ETO9a at D188, generating cleavage fragments that are deleterious to the 
AML1-ETO expressing Kasumi-1 cells, resulting in impaired proliferation, increased 
apoptosis, and decreased colony formation ability in methylcellulose.  Bortezomib 
treatment increased the overall survival of mice transplanted with AML1-ETO9a 
expressing cells (34 days for Bortezomib at 2 mg/kg, compared to 19 days for control 
treated mice).  The anti-leukemic effects of Bortezomib may relate to its ability to 
downregulate c-KIT and to generate AML1-ETO cleavage fragments122. 
Another study suggests that Bortezomib exerts its antileukemic effects by repressing 
the transcription factor specificity protein 1 (SP1)123.  Using a ChIP-chip analysis 
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of AML1-ETO expressing CD34+ cells, the Alvarez laboratory determined that the 
majority of AML1-ETO target genes did not contain an AML1 consensus binding site 
in their regulatory regions, but instead showed enrichment for Sp1 consensus binding 
sites.  Many of these genes are part of the Wnt/β-catenin pathway and the canonical 
stem cell pluripotency pathway, according to Ingenuity Pathways Analysis.  AML1-
ETO can directly bind SP1, and mithramycin A, an Sp1 inhibitor, can induce the re-
expression of AML1-ETO targets that possess an Sp1 consensus binding site (but that 
lack an AML1 consensus binding site)124.  By repressing SP1, Bortezomib may 
similarly alleviate AML1- ETO target gene repression.  Regardless of the potential 
mechanism, Bortezomib is being evaluated in the treatment of AML. 
 
The ability of AML1-ETO to recruit HDAC complexes to many of its target genes has 
prompted the testing of HDAC inhibitors on t(8;21)+ AML cells.  Trichostatin A 
(TSA) is a hydroxamic acid-based inhibitor of class I and II HDACs125; it can alleviate 
AML1-ETO-mediated repression of AML1 target genes in reporter assays51 and lead 
to the rapid degradation of AML1-ETO in Kasumi-1 cells.  Similar results have been 
seen with Depsipeptide/romidepsin (DEP), another HDAC inhibitor that triggers the 
proteasomal degradation of AML1-ETO in Kasumi-1 cells126,127,128.  Because 
oncogenes like AML1-ETO are frequently bound to cellular chaperones like HSP90, 
the Hiebert laboratory investigated the effects of the HSP90 inhibitor 17-allylamino-
geldanamycin (17-AAG) on Kasumi-1 cells and found that 17-AAG also triggered the 
degradation of AML1-ETO.  This effect was not enhanced by co-treatment with DEP, 
suggesting that both inhibitors act on the same pathway; indeed, subsequent 
investigations demonstrated that treatment with DEP releases AML1-ETO from 
HSP90, thereby facilitating its degradation127.  The ability of HDAC inhibitors to 
alleviate AML1-ETO-mediated repression and induce the degradation of AML1-ETO 
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protein, possibly via acetylation of HSP90128,129, highlights their potential in treating 
t(8;21)+ AML. 
 
Acetylation can be regulated by factors other than HDACs, however, and we have 
discovered an important role for the lysine acetyltransferase p300 in t(8;21)+ 
leukemia.  p300 has been shown to bind to the C terminus of AML120 and acetylate 
residues K24 and K43, thereby augmenting AML1 transcriptional activity130.  
Although the C terminus of AML1 is lost in the AML1-ETO fusion, we have found 
that AML1-ETO can still bind to p300 via the NHR1 domain of ETO.  Binding of 
p300 to this region is required for the acetylation of AML1-ETO (and AML1-ETO9a) 
at the K24 and K43 residues.  This acetylation is detectable in leukemia cells isolated 
from t(8;21)+ AML patients, and is essential for the ability of AML1-ETO to increase 
the self-renewal of human CD34+ cells.  Acetylated AML1-ETO co-localizes with 
p300 at gene regulatory regions to cooperatively upregulate the expression of target 
genes that may be involved in self-renewal, such as ID1, p21 and EGR1.  In contrast, 
overexpression of an AML1-ETO acetylation mutant (AE K43R) in human or murine 
HSPCs had little effect on self-renewal.  Compared to leukemogenic AML1-ETO9a, 
the AML1-ETO9a acetylation mutant (AE9a K43R) was unable to cause AML in 
mice, demonstrating that K43 acetylation is required for leukemogenesis in this mouse 
model131.  Treatment of Kasumi-1 cells and t(8;21)+ AML patient cells with p300 
inhibitors, such as Lys-CoA-TAT132 or C646133, resulted in growth inhibition, without 
effecting normal CD34+ cell growth.  Similarly, treatment of AML1-ETO9a 
expressing mouse leukemia cells ex vivo with Lys-CoA-TAT or C646 prior to 
transplantation resulted in a significant increase in the median survival of recipient 
mice, compared to the DDDD-Tat or C37 treated controls.  Although AML1-ETO can 
be regulated by a variety of post-translational modifications134, it appears that site-
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specific acetylation contributes significantly to its role as a leukemogenic oncogene.  
This work identifies p300 as a valid therapeutic target for t(8;21)+ AML. 
 
Significant progress has been made in developing mouse models that recapitulate 
features of t(8;21)+ AML.  And while these models have allowed investigators to 
explore avenues amenable to therapeutic targeting, the requirements for AML1-ETO 
driven leukemogenesis remain largely unknown.  The two-hit hypothesis accounts for 
the ability of several factors to initiate leukemia in concert with AML1-ETO, but fails 
to account for the ability of others to initiate the same t(8;21)+ disease.  Furthermore, 
the handful of mutations that successfully cooperate with AML1-ETO are present in 
very few t(8;21)+ AML patients and cannot represent the totality of mutations capable 
of contributing to AML1-ETO positive leukemogenesis.   
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VOLUME I: 
ONE BY ONE COOPERATIVITY STUDIES 
 
AML1-ETO and WT1 
 
We have attempted to delineate the requirements for AML1-ETO driven 
leukemogenesis by investigating the leukemia that develops upon expression of 
AML1-ETO in WT1 overexpressing cells.  While it has been shown that recipient 
mice die of an aggressive AML 1 to 4 months after transplantation with WT1 
transgenic cells transduced with AML1-ETO72, such a model employs artificially high 
levels of AML1-ETO expression not reflective of t(8;21)+ cells.  An experimental 
setting in which WT1 is overexpressed in AML1-ETO transgenic cells, cells in which 
AML1-ETO is expressed at endogenous levels, has not been explored.  If co-
expression of AML1-ETO and WT1 is capable of satisfying the two-hit hypothesis, 
then an identical leukemia should result after a similar latency.  
 
To determine if a similar leukemia can be achieved under experimental settings 
comparable to those of t(8;21)+ AML patients, we transduced bone marrow cells from 
AML1-ETO transgenic mice (AML1-ETO-Stop/+; Mx1-Cre+/-)32 with WT1 and 
transplanted these cells into recipient mice.  1 month post-transplantation, the 
recipients were treated with poly(I:C) to induce expression of AML1-ETO from the 
AML1 promoter.  Approximately 5 months post-treatment with poly(I:C), 1 of 5 
recipient mice developed AML (Figure 1A).  The leukemic blasts possessed an 
immunophenotype reminiscent of a HSPC; they stained positive for c-KIT, with a 
subset also staining positive for SCA-1 (Figure 1B).  These blasts were capable of  
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transplanting the leukemia into secondary recipients (Figure 1C), with the c-KIT and 
SCA-1 double-positive subset becoming the dominant population.  At euthanasia, both 
primary and the secondary recipients harbored leukemic blasts in the bone marrow in 
excess of 20% (Figure 1D).  Blast cells were also present in the spleen (Figure 1E).   
Figure 1A.  Kaplan-Meier plot of mouse survival after transplantation with bone 
marrow cells from AML1-ETO-Stop/+; Mx1-Cre+/- mice, transduced with the given 
retroviral expression vector.  Empty Vector (n = 5); WT1 (n = 5). 
Figure 1B.  Representative flow cytometry analysis of the bone marrow and spleen 
of the leukemic mouse transplanted with AML1-ETO-Stop/+; Mx1-Cre+/- bone 
marrow transduced with WT1. 
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Figure 1C.  Kaplan-Meier plot of mouse survival after transplantation with 2x106 
spleen cells from the leukemic animal of indicated primary transplantation group   
(n = 5). 
Figure 1D.  Representative flow cytometry analysis of the bone marrow and spleen 
of secondary transplant recipients at euthanasia. 
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Although leukemia penetrance in this experimental setting was low as compared to the 
setting in which WT1 transgenic cells are transduced with AML1-ETO, a leukemia 
with similar features was capable of being induced.  Expression of AML1-ETO at 
endogenous levels does not preclude leukemogenesis.  While WT1 is not a traditional 
Class I mutation, its upregulation is an event that, when paired with AML1-ETO, 
satisfies the basic principles of the two-hit hypothesis.  
 
AML1-ETO and PTEN Loss 
 
A secondary event that more closely resembles a Class I mutation, and which may be 
capable of cooperating with AML1-ETO in vivo, is PTEN loss.  PTEN disruption is 
Figure 1E.  Representative hematoxylin and eosin staining of the bone marrow and 
spleen of the leukemic mouse transplanted with AML1-ETO-Stop/+; Mx1-Cre+/- bone 
marrow transduced with WT1. 
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not a hallmark of t(8;21)+ AML; however, AML1-ETO has been found to localize at 
the AML1 binding site present in the PTEN promoter and downregulate PTEN 
expression135.  Furthermore, the constitutive signaling through AKT that PTEN 
disruption engenders136 has been documented in Kasumi-1 cells137 and in cells isolated 
from the leukemia initiated by AML1-ETO and MPL co-expression138.  Of note, both 
Kasumi-1 cells and the aforementioned leukemic blasts are hypersensitive to AKT 
inhibition139,138.   
 
To determine whether constitutive signaling through AKT could contribute to AML1-
ETO leukemogenesis, we chose to express AML1-ETO endogenously in PTEN 
deleted cells by crossing AML1-ETO transgenic mice32 (AML1-ETO-Stop/+; Mx1-
Cre+/-, hereafter AE) to PTEN conditional knockout mice140 (Ptenfl/fl; Mx1-Cre+/-, 
hereafter PTEN).  Bone marrow cells from the aforementioned mice, as well as from 
the resultant progeny (AML1-ETO-Stop/+; Ptenfl/fl; Mx1-Cre+/-, hereafter AE / PTEN) 
were then transplanted into lethally irradiated recipient mice.   
 
Previous studies have demonstrated that 5 days after poly(I:C) injection PTEN mice 
develop a myeloproliferative neoplasm which subsequently progresses to frank 
leukemia.  In contrast, recipients of PTEN cells that are treated with Poly(I:C) 6 weeks 
post-transplantation remain healthy; the PTEN deleted cells initially possess a 
proliferative advantage over co-transplanted wild type (WT) cells, but exhaust and 
deplete over time140.   
 
We similarly find that the majority of PTEN recipient mice remain healthy, with a 
select few developing T-cell lymphoma.  AE recipient mice develop 
leukemia/lymphoma after a median latency of 485 days, while AE / PTEN recipients  
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Figure 2A.  Kaplan-Meier plot of mouse survival after transplantation with bone 
marrow cells from WT, AE, PTEN, or AE / PTEN mice.  WT (n = 14); AE (n = 5); 
PTEN (n = 18); AE / PTEN (n = 19).  
Figure 2B.  Representative hematoxylin and eosin staining of the indicated organs 
of an AE / PTEN mouse with leukemia/lymphoma and a healthy AE mouse.  
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develop leukemia/lymphoma after a significantly accelerated latency of 321 days 
(Figure 2A).  The immunophenotype of the AE / PTEN disease is more reflective of 
that found in AE recipients than of the T-cell lymphoma present in a subset of PTEN 
recipients.  These cells, which occupy the bone marrow, spleen, liver, and thymus of 
recipients (Figure 2B), stain negative for the immature cell marker c-KIT.  Instead, 
they are positive for SCA-1 and both mature cell markers CD3E and MAC-1 (Figure 
2C).  While the presence of MAC-1 on cells otherwise lymphoid in their surface 
marker expression is abnormal, it may reflect the dysregulation of surface protein 
genes.  Notably, blast cells in a select number of AE / PTEN recipients are positive for 
phosphorylated AKT (Figure 2D), suggesting that PTEN deletion in these cells 
amplifies AKT signaling to a level not detectable in AE blasts.   
 
 
 
 
 
 
 
 
 
 
 
 
 
While this model of t(8;21)+ leukemia demonstrates that PTEN loss can synergize 
with AML1-ETO to accelerate AE recipient disease, it also fails to accurately 
Figure 2C.  Representative flow cytometry analysis of the peripheral blood, bone 
marrow, and spleen of an AE / PTEN mouse with leukemia/lymphoma, as well as 
healthy AE and PTEN mice.   
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reproduce the phenotype of AML.  PTEN loss has been found to promote 
aneuploidy140, which could result in AE / PTEN cells harboring mutations beyond 
enhanced AKT signaling.  An alternative approach to investigating cooperativity 
between AML1-ETO and AKT signaling would employ a constitutively activated 
form of the protein, myristoylated AKT1141.  Perhaps under this experimental setting, 
the affects of a single event would allow for an AML1-ETO positive disease to 
develop that more closely resembles that  of t(8;21)+ AML patients.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ultimately, investigations into the requirements for AML1-ETO driven 
leukemogenesis will be slow and cumbersome if they depend upon cherry-picking 
secondary events one at a time.  Instead, the field would benefit from a method that 
Figure 2D.  Immunohistochemistry for phosphorylated-AKT, B220, and CD3e 
performed on the thymus of an AE / PTEN and an AE mouse with leukemia/lymphoma.   
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identifies secondary events capable of cooperating with AML1-ETO in a more rapid 
and unbiased manner.  To this end, we have developed an approach that integrates 
both mouse and human AML genomics.  We then validated this approach by 
demonstrating that two of the three candidates identified by our method are capable of 
cooperating with AML1-ETO to develop an AML reflective of that in t(8;21)+ 
patients in vivo.      
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VOLUME II:  
INTEGRATED APPROACH IDENTIFIES COOPERATING EVENTS* 
 
To facilitate the discovery of cooperating mutations in t(8;21)+ AML, and develop 
mouse models capable of revealing new mechanisms of leukemogenesis and new 
therapeutic avenues, we chose to investigate two AML1-ETO driven models of AML 
that may depend upon the acquisition of secondary events for leukemogenesis.  
Expression of AML1-ETO in p21 null cells or expression of AML1-ETO9a in WT 
cells, can induce fully penetrant AML after a prolonged latency75,86.  It is thought that 
loss of p21 in vivo prevents the repair of damaged DNA and allows for the 
accumulation of mutations and cooperating alleles in AML1-ETO+ hematopoietic 
progenitors142,143,144,145,146,147.  Studies of AML1-ETO9a driven leukemia have found 
deregulated expression of DNA repair genes148,149,150, which might facilitate a similar 
acquisition of cooperating secondary events.  We hypothesized that we could identify 
and credential disease alleles in t(8;21)+ AML through integrative genomic studies of 
human AML and the murine AMLs that arise from these models. 
 
Identification of Phenotypically Similar Mouse Models of t(8;21)+ AML  
 
We first expressed AML1-ETO or AML1-ETO9a in fetal liver cells isolated from WT 
or p21-/- mice. All transplant recipients of AML1-ETO expressing p21-/- cells 
developed lethal AML with a median latency of 201 days.  Expression of AML1-
ETO9a in WT or p21-/- cells resulted in a fully penetrant, lethal leukemia after a 
                                                          
* Hatlen MA, Arora K, Vacic V, Grabowska EA, Liao W, Riley-Gillis B, Oschwald DM, Wang L, 
Joergens JE, Shih AH, Rapaport F, Gu S, Voza F, Asai T, Neel BG, Kharas MG, Gonen M, Levine RL, 
and Nimer SD.   Integrative Analysis of the Mutational Landscape of Mouse and Human AML 
Identifies Functionally Relevant Leukemia Disease Alleles. (2015). 
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median latency of 175 and 196 days, respectively (Figure 3A).  At euthanasia, 
leukemic mice had anemia, thrombocytopenia, and elevated white blood cell counts 
(Figure 3B).  We observed blast cell accumulation in the bone marrow, liver, and 
spleen (Figure 3C), resulting in splenomegaly (Figure 3D).  The GFP+ blast cells 
display an immature immunophenotype; they are negative for lineage markers and 
SCA-1, but are c-KIT positive (Figure 1 E).  Leukemia with an identical 
immunophenotype develops (data not shown) within secondary recipients (Figure 3F).  
The observations that these mouse models are phenotypically similar and develop 
AML with similar penetrance and latency suggest that they have acquired similar 
secondary events. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3A.  Kaplan-Meier plot of mouse survival after transplantation with E14.5 
fetal liver cells transduced with the given retroviral expression vector.  WT pBEX 
(n = 12); WT AML1-ETO9a (n =17); WT AML1-ETO (n =17); p21-/- pBEX (n 
=11); p21-/- AML1-ETO9a (n =10); p21-/- AML1-ETO (n =12).  
Figure 3B.  Peripheral blood counts at euthanasia of leukemic mice transplanted 
with cells expressing AE9a or AE, as well as control mice transplanted with cells 
expressing pBEX.  WBC indicates white blood cells; RBC, red blood cells.  
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Figure 3C.  Representative hematoxylin and eosin staining of the bone marrow, spleen, 
and liver of the following leukemic mice at euthanasia: WT AE9a, p21-/- AE9a, and 
p21-/- AE.  Control mice, WT pBEX and WT AE, lack the accumulation of blast cells 
present in leukemic mice.  Bar represents 50 μm. 
Figure 3D.  At euthanasia, leukemic mice exhibit significant splenomegaly compared 
to control mice sacrificed at a similar time point.  WT pBEX (n = 2); WT AE9a (n =8);  
p21-/- AE9a (n =5); p21-/- AE (n =7). 
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Figure 3E.  Representative flow cytometry analysis of the bone marrow of mice 
transplanted with WT or p21-/- cells transduced with the given retroviral expression 
vector.  Cells were analyzed for the expression of a variety of lineage markers (Lin), as 
well as for c-Kit, Sca-1, and GFP. 
Figure 3F.  Kaplan-Meier plot of mouse survival after transplantation with 2x106 
spleen cells from leukemic mice of the indicated primary transplantation group.  WT 
AE9a (n =15); p21-/- AE9a (n =13); p21-/- AE (n =15). 
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Mouse Models of AML Reproduce the Genomic Landscape of Human AML 
 
We next investigated the mutational landscape of these murine AMLs and compared it 
to a somatic mutational analysis of other murine AML models and AML patients151.  
Sequence analysis revealed that a majority of murine AML samples were highly 
concordant with pooled control samples, allowing us to exclude germline variants.  
We did not observe a significant difference in the number of variants detected or genes 
targeted in the mouse models compared to AML patient samples (Figure 4A-C).  
When we restricted our analysis to genes for which human-mouse orthology is known, 
we observed a significant enrichment in the murine AML for genes (hypergeometric   
p ≤ 4.26x10-20) (Figure 4D) and protein domains (hypergeometric p ≤ 4.23x10-3) 
mutated in human AML.  Domains mutated in both human and murine AML were 
similarly affected by recurrent mutations (Spearman correlation of domain p-values     
r = 0.53, p ≤ 2.73x10-8) (Figure 4E).  We next investigated the frequency of mutations 
in different protein classes, and while the protein classes targeted in murine vs. human 
AML were significantly different (p = 0.049), we found no differences in the protein 
classes targeted in AML1-ETO/AML1-ETO9a murine AML vs. human t(8;21)+ AML  
(p = 0.327) (Figure 4F).  
 
 
 
 
 
 
 
 Figure 4A.  The number of non-synonymous mutations in the GFP+ spleen cells of 
leukemic mice and in human AML patients with the given cytogenetic abnormality. 
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Figure 4B.  The number of insertion and deletion events in the GFP+ spleen cells of 
leukemic mice and in human AML patients with the given cytogenetic abnormality. 
Figure 4C.  The number of genes harboring non-synonymous, insertion, or deletion 
events in the GFP+ spleen cells of leukemic mice and in human AML patients with the 
given cytogenetic abnormality. 
Figure 4D.  A stacked plot of the genes that are mutated in ≥ 2% of human AML 
samples and ≥ 8% of mouse AML samples.  67.90% of genes mutated in leukemic mice 
are also mutated in human AML patients, while only 5.07% of genes with a protein-
coding mutation in AML patients are also mutated in leukemic mice.  This enrichment 
is significant (p ≤ 4.26x10-20). 
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Figure 4E.  Of the genes that harbor protein-coding mutations in both leukemic mice 
and human AML patients, the fraction of protein domains that are mutated in both 
species (red) or in only one species (blue) is depicted.  The color intensity increases 
with the number of mutations in a given protein domain.  65.07% of these protein 
domains are mutated in both species, demonstrating enrichment (p ≤ 4.23x10-3).  
Domains similarly affected are recurrently mutated (Spearman correlation of domain   
p-values, r = 0.53, p ≤ 2.73x10-8) 
Figure 4F.  Genes mutated in mouse and human AML belong to the given protein 
classes.  There is a significant difference in the classes that are targeted between mouse 
and human AML (p = 0.049), but not between t(8;21)+ mouse and human AML          
(p = 0.327). 
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Integrated Genomic Approach Identifies Potential Cooperating Events in 
t(8;21)+ AML 
 
We next sought to mine the mutational data to identify mutations capable of 
cooperating with AML1-ETO, initially focusing our efforts on the 424 genes mutated 
in both human and murine AML, and then further narrowing our focus to those genes 
that were also significantly mutated (defined as Genome MuSiC SMG FDR ≤ 30%).  
This reduced the number of potential candidates from 424 to 38 human genes, 
representing 45 mouse orthologues (Figure 5A).  We focused on the mouse 
orthologues which were significantly mutated (FDR ≤ 10%) in AML1-ETO driven 
leukemias, and not in MLL-AF9 driven leukemia, and identified 38 mouse genes 
which met this criteria (Figure 5B).  These 38 genes correspond to 32 human 
orthologues, which include 3 alleles annotated in COSMIC as cancer genes152: TET2, 
PTPN11, and THRAP3. 
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Figure 5A.  The patients that harbor non-synonymous mutations in genes that are 
significantly mutated in mouse and human AML (FDR ≤ 30%). 
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Figure 5B.  The types of mutations present in mouse AML samples that occur in genes 
significantly mutated in mouse and human AML.  Those genes that are significantly 
mutated in a given mouse AML group (FDR ≤ 10%) are highlighted in blue under the 
given group. 
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Expression of AML1-ETO in Tet2 Null Cells Generates a Novel Model of t(8;21)+ 
AML  
 
The variants detected in TET2 in AML patients include nonsense, frameshift, and 
missense mutations within conserved domains, consistent with loss of TET2 
enzymatic function (Table 3).  Notably, 3 of the 29 t(8;21)+ AML patients enrolled in 
the ECOG E1900 trial153 harbored TET2 mutations (Figure 5C).  In vivo, monoallelic 
or biallelic loss of Tet2 in the hematopoietic compartment of mice results in 
myeloproliferation and extramedulary hematopoiesis, but not AML154,155.   
 
To determine if loss of Tet2 can cooperate with AML1-ETO in vivo, we transduced 
bone marrow cells from Vav-Cre+Tet2-/- (Tet2 KO) mice with AML1-ETO or AML1-
ETO9a and transplanted the cells into lethally irradiated recipients.  All mice 
transplanted with AML1-ETO expressing Tet2 KO cells developed fully penetrant 
leukemia, while mice transplanted with AML1-ETO9a expressing Tet2 KO cells  
Figure 5C.  A schematic of TET2 and the location of mutations identified in t(8;21)+ 
AML patients. 
Figure 5D.  A schematic of PTPN11 and the location of mutations identified in AML 
patients. 
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Table 3.  The TET2 Mutations in AML Patients 
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developed a significantly accelerated leukemia with a median latency of 118 days      
(p < 0.0001) (Figure 6A).  At euthanasia, leukemic recipients had anemia, 
thrombocytopenia, elevated white blood cell counts (Figure 6B), and blast cell 
infiltration into the liver and spleen, with consequent splenomegaly (Figure 6C-D).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The GFP+ blast cells are lineage negative, SCA-1 positive or negative, and c-KIT 
positive (Figure 6E).  The observed cooperativity between Tet2 loss and AML1-ETO 
in vivo implicates TET2 loss-of-function mutations in t(8;21)+ AML patients as 
functional cooperating events. 
Figure 6A.  Kaplan-Meier plot of mouse survival after transplantation with bone 
marrow cells transduced with the given retroviral expression vector.  WT pBEX (n =5); 
WT AE9a (n =7); WT AE (n =10); Tet2 KO pBEX (n =12); Tet2 KO AE9a (n =13); 
Tet2 KO AE (n =23). 
Figure 6B.  Peripheral blood counts of mice transplanted with Tet2 KO cells 
expressing AE9a, AE, or pBEX.   
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Figure 6C.  Representative hematoxylin and eosin staining of the bone marrow, spleen, 
and liver of leukemic mice transplanted with Tet2 KO AE or AE9a cells.  Tet2 KO 
pBEX recipients lack the accumulation of blast cells present in leukemic mice. Bar 
represents 50 μm.   
Figure 6D.  At euthanasia, leukemic mice exhibit significant splenomegaly compared 
to control mice sacrificed at a similar time point.  Tet2 KO pBEX (n =2); Tet2 KO AE 
(n =9); Tet2 KO AE9a (n =9).  From top to bottom: Liver, kidney, spleen.   
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 Figure 6E.  Flow cytometry analysis of the bone marrow and spleen of mice 
transplanted with Tet2 KO cells transduced with the given retroviral expression vector.  
Lin indicates lineage panel; S indicates Sca-1; K indicates c-Kit. 
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Expression of AML1-ETO with PTPN11 D61Y Generates a Novel Model of 
t(8;21)+ AML  
 
The PTPN11 mutations that we observe in human and mouse AML occur within 
highly conserved regions of PTPN11; the SHP2 domains and the domain required for 
PTPN11 phosphatase activity (PTP) (Figure 5D, Table 4).  Because PTPN11 is auto- 
 
Table 4.  The PTPN11 Mutations in AML Patients 
 
 
 
 
 
 
 
 
inhibited by interactions between N-SHP2 and PTP156,157, mutations in these domains 
activate phosphatase activity, stimulating RAS signaling158,159.  Of note, PTPN11 
A72V has been reported in a t(8;21)+ AML patient160 and activating RAS mutations 
occur in 8-10% of AML1-ETO+ AML patients, implicating constitutive MAPK 
signaling in AML1-ETO+ AML pathogenesis60.  We previously showed that mice 
expressing the constitutively active D61Y mutation in the hematopoietic compartment 
(Ptpn11D61Y) develop a fatal myeloproliferative neoplasm.  However, bone marrow 
cells from these mice fail to engraft beyond 20 weeks in transplant recipients and do 
not induce AML in vivo161.  We therefore transduced bone marrow cells from 
51 
Ptpn11D61Y mice with AML1-ETO and transplanted the cells into lethally irradiated 
recipients.  Mice expressing both alleles developed fatal AML (Figure 7A).   
 
 
 
 
 
 
 
 
 
 
 
At euthanasia, leukemic mice had elevated white blood cells counts, anemia, 
thrombocytopenia (Figure 7B), and blast cell accumulation in the bone marrow, liver 
and spleen (Figure 7C-D).  These GFP+ blasts were SCA-1 negative and c-KIT 
positive (Figure 7E) and capable of transmitting the disease into secondary recipients 
(Figure 7F-H, Table 5). Thus, the mutant PTPN11 protein can cooperate with AML1-
ETO to induce AML in vivo. 
 
 
 
 
 
 
 
Figure 7A.  Kaplan-Meier plot of mouse survival after transplantation with bone 
marrow cells transduced with the given retroviral expression vector.  WT pBEX          
(n =10); WT AE (n =15); PTPN11 D61Y pBEX (n =10); PTPN11 D61Y AE (n =15). 
Figure 7B.  Peripheral blood counts at euthanasia of leukemic PTPN11 D61Y AE 
mice, as well as control mice. 
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Figure 7C.  Representative hematoxylin and eosin staining of the bone marrow, spleen, 
and liver of the given transplant recipients.  Bar represents 50 μm. 
Figure 7D.  At euthanasia, leukemic mice exhibit splenomegaly compared to control 
mice sacrificed at a similar time point.  WT pBEX (n =3); WT AE (n =3); PTPN11 
D61Y pBEX (n =3); PTPN11 D61Y AE (n = 6).  From top to bottom: Liver, kidney, 
and spleen. 
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Figure 7E.  Flow cytometry analysis of the bone marrow and spleen of mice 
transplanted with WT or PTPN11 D61Y cells transduced with the given retroviral 
expression vector.   
Figure 7F.  Kaplan-Meier plot of mouse survival after transplantation with spleen cells 
from a leukemic PTPN11 D61Y AE mouse (n =5). 
Figure 7G.  Secondary recipients of PTPN11 D61Y AE leukemic cells develop 
splenomegaly.  From top to bottom: Liver, kidney, and spleen. 
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Table 5.  Peripheral Blood Counts of Recipients of leukemic Ptpn11D61Y AE cells 
 
 
 
 
 
 
Dependence of t(8;21)+ Models on Secondary Events  
 
Given that the mouse models generated by expressing AML1-ETO9a or AML1-ETO 
in transplanted p21 null cells reproduce the genetic landscape of human AML and 
acquire mutations capable of cooperating with AML1-ETO, we decided to investigate 
Figure 7H.  Representative flow cytometry analysis of the bone marrow and spleen of 
mice transplanted with leukemic PTPN11 D61Y AE cells. 
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these models' requirements for leukemia progression in the hopes of identifying new 
therapeutic targets for t(8;21)+ AML.   
 
While lack of p21 in these leukemias is thought to promote leukemogenesis by 
facilitating the acquisition of secondary, cooperating events, the absence of p21 itself 
may be necessary for leukemia progression.  To ascertain the role of p21 in these 
leukemias, we expressed p21 exogenously in p21 null leukemic spleen cells 
expressing AML1-ETO and either transplanted the cells into sub-lethally irradiated 
recipients or placed the cells into methylcellulose media. 
 
Recipients of leukemic cells expressing p21 died of leukemia after a median latency of 
55 days, a latency significantly longer than that of mice receiving leukemic cells null 
for p21 (Figure 8A).   
 
 
 
 
 
 
 
 
Figure 8A.  Kaplan-Meier plot of mouse survival after transplantation with spleen cells 
from a leukemic p21 null AE mouse, which exogenously express either an empty vector 
or a vector containing the cDNA for p21 (n =5). 
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Similarly, while leukemic cells exogenously expressing p21 showed no impairment in 
their ability to form colonies that consistently replated in methycellulose media, these 
cells overall form fewer colonies than leukemic cells null for p21 (Figure 8B). 
 
 
 
 
 
 
 
 
 
To further investigate the dependence of leukemia maintenance on p21, we 
transplanted colonies from the fourth methylcellulose replating into sub-lethally 
irradiated recipients.  Notably, recipients of cells expressing p21 developed leukemia 
after a significantly extended median latency of 66 days, compared to recipients of 
p21 null cells, which developed leukemia after a median latency of 33 days.  When 
leukemias from these transplant recipients were serially transplanted, a majority of the 
secondary recipients of p21 expressing leukemia cells survived the entirety of the 
observation period without developing disease, while all secondary recipients of p21 
null leukemia cells succumbed to disease after a median latency of 41 days (Figure 
8C).  Interestingly, at euthanasia, all recipients lacked expression of p21, regardless of 
Figure 8B.  The ability of leukemic spleen cells null for p21 and expressing AE to form 
colonies that replate in methylcellulose after an empty vector or cDNA for p21 is 
exogenously expressed (n=3).  
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whether they received p21 null cells or p21 null cells exogenously expressing the gene 
(Figure 8D).  This result suggests that p21 plays a role not only in the initiation of 
these leukemias, but in their maintenance as well. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8C.  Kaplan-Meier plot of mouse survival after serial transplantation with 
colonies of leukemic cells expressing the given vector from the fourth methylcellulose 
replating (n =10). 
Figure 8D.  The expression level of p21 in various cell lines or in primary spleen cells:  
293T cells transfected with an empty vector or p21; GFP+ spleen cells from leukemic 
mice transplanted with p21 null AE cells exogenously expressing empty vector or a 
vector containing p21 cDNA; GFP+ spleen cells from a mouse transplanted with WT 
cells expressing AE9a; p21-/- or WT spleen cells; a cell line generated from the in vitro 
culture of leukemic spleen cells from a mouse transplanted with WT cells expressing 
AE9a.  
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In studying leukemias expressing AML1-ETO9a, or AML1-ETO in the p21 null 
setting, we were able to identify Tet2 loss as an event capable of cooperating with 
AML1-ETO to induce leukemia.  Tet2 loss also significantly increased the latency of 
AML1-ETO9a leukemias.  Given the role of Tet2 as a demethylating agent, we 
decided to investigate whether a global demethylating agent, 5-Azacytidine, could 
impact the maintenance of primary leukemias.  When we treated mice receiving 
leukemic cells expressing AML1-ETO9a with 5-Azacytidine, we found that the 
median latency was significantly extended to 77 days.  Vehicle treated mice died of 
leukemia after a median latency of 38 days (Figure 8E).  A specific methylation 
profile may be necessary for the maintenance of AML1-ETO9a and AML1-ETO 
leukemias. 
 
  
Figure 8E.  Kaplan-Meier plot of mouse survival after treatment with 100ug of 5-
Azacytidine.  Mice were transplanted with spleen cells from a leukemic WT AE9a 
mouse and treatment occurred for 5 consecutive days at 30 and 60 days post-
transplantation  (WT AE9a - Vehicle, n =5; WT AE9a - 5 Azacytidine, n =10). 
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DISCUSSION* 
 
Although the first report of t(8;21) occurred over 40 years ago, the requirements for 
AML1-ETO driven leukemogenesis remain largely unknown.  Our own efforts to 
identify WT1 overexpression and PTEN loss as events capable of cooperating with 
endogenous AML1-ETO were not particularly successful, despite the fact that these 
events fulfilled tenets of the two-hit hypothesis.  These two events yielded a leukemia 
with incomplete penetrance and a leukemia/lymphoma that did not reflect t(8;21)+ 
patient disease, respectively.   
 
In an effort to more rapidly identify AML1-ETO cooperating partners and better 
understand the requirements for t(8;21)+ leukemogenesis, we investigated the 
genomics of both mouse and human AML.  Exome sequencing revealed that two 
phenotypically similar AML1-ETO driven murine leukemia models possess a 
mutational landscape reflective of each other and human AML patients, especially in 
terms of the number of acquired secondary events, the genes involved, and the protein 
domains targeted.  By identifying genes that were significantly mutated in AML 
patients and the mouse models, we were able to identify Tet2 loss and PTPN11 D61Y 
as secondary events capable of cooperating with AML1-ETO in vivo.   
 
The observation that Tet2 loss can cooperate with AML1-ETO challenges the 
traditional "two-hit hypothesis" of AML, which posits that AML1-ETO commonly 
cooperates with mutations that activate oncogenic signaling68,29.  Our data suggest that 
                                                          
* Hatlen MA, Arora K, Vacic V, Grabowska EA, Liao W, Riley-Gillis B, Oschwald DM, Wang L, 
Joergens JE, Shih AH, Rapaport F, Gu S, Voza F, Asai T, Neel BG, Kharas MG, Gonen M, Levine RL, 
and Nimer SD.   Integrative Analysis of the Mutational Landscape of Mouse and Human AML 
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mutations in epigenetic regulators can potently cooperate with AML1-ETO in vivo.  
Given that neomorphic mutations in IDH1/2 and loss-of-function mutations in WT1 
also attenuate TET2 function and reduce DNA hydroxymethylation in 
vivo162,163,164,165, it will be important to determine if altered DNA hydroxymethylation 
and consequent methylation is a common pathogenetic event in AML1-ETO+ AML.  
Indeed our finding that a global demethylating agent attenuates the oncogenic effects 
of AML1-ETO9a implicates DNA methylation as a critical component of t(8;21)+ 
AML. 
 
To better define the role of methylation in t(8;21)+ AML, we believe that studies 
should be initiated which utilize mouse models of AML1-ETO expression and either 
IDH1/2 mutations, WT1 mutations, Tet2 loss, or WT1 overexpression.  We have 
demonstrated that the latter two events are sufficient for leukemogenesis in t(8;21)+ 
cells despite their antithetical impact on 5hmC; WT1 overexpression is synonymous 
with increased global 5hmC, a feature absent from Tet2 null cells164.  Measuring the 
levels of 5hmC in these AML1-ETO driven mouse models will be critical to 
uncovering whether loss of 5hmC is an event conserved across AML1-ETO driven 
models which rely upon co-occurring mutations in epigenetic regulators, or if, rather 
than global methylation, it is the hypermethylation of specific gene targets that is 
conserved across these models.  WT1 is responsible for recruiting TET2 to gene 
targets such that their expression is activated165.  When WT1 is overexpressed, its 
promiscuous activity may result in the recruitment of TET2 to novel genes at the 
expense of proper targets, ensuring the continued methylation and repression of these 
targets.  Similarly, in the case of WT1 loss-of-function mutations or neomorphic 
IDH1/2 mutations, gene targets may fail to be demethylated because of WT1's 
inability to recruit TET2 or attenuated TET2 function.  Gene silencing of WT1/TET2 
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targets, such as BTRC, DACT1, and TBL1X165, may represent a novel mechanism of 
leukemogenesis in t(8;21)+ AML.  For this reason, explorations into the epigenetic 
profile of t(8;21)+ AML with concurrent mutations in epigenetic regulators, and their 
potential response to epigenetic therapies, are warranted.   
 
Additional mechanistic studies can also be performed on the primary AML1-ETO 
driven models of leukemogenesis, those models which reflect the mutational profile of 
AML patients and that rely upon the absence of p21.  While we initially hypothesized 
that the role of p21 in these models was to facilitate the acquisition of secondary 
disease alleles, it has become clear that p21 loss is necessary not only for leukemia 
initiation but also progression.  p21 plays a number of biological roles, from ensuring 
the repair of damaged DNA to regulating cellular self-renewal and cell cycle 
progression166.  To determine which of these particular roles impacts leukemia 
progression, and to potentially identify new avenues of therapy for t(8;21)+ AML, it 
would be beneficial to serially transplant p21 null, AML1-ETO expressing leukemia 
cells that have been engineered to exogenously express a mutant form of p21 
incapable of binding cyclin-cdk complexes and regulating cell cycle progression167.  In 
this manner, we could assess whether increased cycling is necessary for leukemia 
maintenance and if cell cycle inhibitors should be investigated for therapeutic efficacy 
in t(8;21)+ AML. 
 
The observation that AML1-ETO can cooperate with PTPN11 D61Y is more 
consistent with the two-hit hypothesis, and further implicates RAS signaling in 
t(8;21)+ AML.  While KRAS is significantly mutated in the human AML panel and 
20% of the AML1-ETO9a expressing P21-/- leukemias had KRAS G12C mutations, 
previous studies pairing AML1-ETO with activating RAS mutations in vivo have had 
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mixed results111,168,169.  Our data showing that PTPN11 D61Y is capable of 
cooperating with AML1-ETO underscores the critical role of dysregulated 
RAS/MAPK signaling in AML1-ETO+ leukemogenesis and suggests that MAPK 
directed therapies should be investigated in this genetically defined t(8;21)+ AML 
subset. 
 
Most importantly, our study illustrates the power of integrating murine and human 
genomic profiling to identify functionally relevant disease alleles in AML.  Previous 
studies in murine solid tumors170 and APL171 have identified functional cooperating 
disease alleles; our data suggest that systematic comparisons of mutational patterns in 
murine and human malignancies is warranted as they can be used to identify 
cooperating disease alleles with mechanistic and therapeutic relevance. 
  
63 
METHODS* 
 
Construction of Expression Vectors and Virus Production 
 
The cDNAs encoding AML1-ETO or AML1-ETO9a were digested with NotI and 
cloned into the NotI multiple cloning site of the MSCV-IRES-BEX plasmid (pBEX), 
upstream of the IRES and blue-excited GFP motifs.  pBEX differs from the previously 
described MigR1 plasmid172 by featuring cDNA for enhanced GFP that has been 
altered such that it can be distinguished from violet-excited GFP173.  To produce 
retrovirus capable of expressing AML1-ETO or AML1-ETO9a, 293T cells were 
cotransfected with a pBEX plasmid and MCV-Ecopac via calcium phosphate 
precipitation174.    
 
Fetal Liver and Bone Marrow Transduction and Transplantation 
 
Fetal liver cells were harvested from E14.5 WT (Jackson Laboratory) or P21-/- (kindly 
provided by Tyler Jacks) C57BL/6 embryos, while bone marrow cells from adult Vav-
Cre+ or Vav-Cre+Tet2-/- C57BL/6 mice154 were harvested 6 days after intraperitoneal 
administration of 200 mg/kg of 5-fluorouracil (Sigma).  Bone marrow cells were 
harvested from 9 week old Mx1-Cre+/- or Ptpn11D61Y mice that had been treated at 3 
weeks with poly(I:C) as previously published161.  Harvested cells were cultured in 
RPMI media supplemented with 10% fetal bovine serum, 10 ng/ml IL-3, 10 ng/ml IL-
6 and 100 ng/ml stem cell factor (Peprotech) prior to transplantation, with 8 ug/ml of 
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polybrene (Sigma) added during spinoculation.  Transduced cells were transplanted 
into 8-10 week old female C57BL/6 recipient mice by tail-vein injection after the 
recipient mice had been lethally irradiated with 950 cGy, given in a split dose 
separated by 3 hours.  Procedures performed on these mice were approved by the 
Institutional Animal Care and Use Committee of Memorial Sloan Kettering Cancer 
Center. 
 
Exome Sequencing 
 
Genomic DNA from GFP+ mouse spleen cells or mouse tail tissue was isolated using 
phenol-chloroform extraction.  Exome capture was performed using the SureSelect 
Mouse All Exon Kit (Agilent Technologies) and sequencing was performed using an 
Illumina platform.  Approximately 80 million reads per sample were acquired after a 
paired-end run with 75 or 100 base-pairs.  Paired-end reads were aligned to the 
NCBIM37.67/mm9 mouse reference genome using the Burrows-Wheeler Aligner, 
BWA aln v0.6.2175 and processed using the best practices pipeline that included 
marking of duplicate reads by the use of Picard tools (http://picard.sourceforge.net), 
and realignment around indels and base recalibration via Genome Analysis Toolkit 
(GATK) ver. 3.1.1176.  Somatic single nucleotide variants (SNVs) were called using 
muTect v1.1.4177, Virmid v1.1.0178 and Strelka v1.0.12179; and somatic indels via 
SomaticIndelDetector v2.3.9 and Strelka.  SNVs and indels were filtered using the 
default filtering criteria as implemented in each of the callers and annotated via snpEff 
and snpSift180,181.  In addition, all germline SNVs and indels identified in the 17 key 
mouse strains as part of the Mouse Genome Project182 were filtered out of the call set.  
To compare our results to what has been previously discovered in human patients, we 
downloaded the BAM files for the 150 human AML exomes from The Cancer 
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Genome Atlas project151. For consistency, we extracted the reads from human exomes, 
re-processed them, and called somatic variants using the same pipeline as for mouse 
exomes. 
 
SMG and Domain Analysis 
 
Significantly mutated genes were identified in mouse and human samples using the 
SMG module from Genome MuSiC v0.4183.  Homology between mouse and human 
genes was based on the mouse-human homolog list downloaded from The Jackson 
Laboratory web site (http://www.informatics.jax.org/homology.shtml).  False 
discovery rates (FDRs) were determined using the likelihood ratio test from the 
Genome MuSiC SMG module.  We annotated proteins with protein domains from 
Pfam-A184, a database of  high quality, manually curated protein families 
(http://pfam.xfam.org). We used the hmmscan algorithm from HMMER3.0 package to 
match protein sequences against the Pfam-A database. 
 
Statistical Analysis 
 
Statistical significance between two groups was assessed using the Student's t-test 
with Welch's correction; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; n.s., 
not significant.  The hypergeometric test was used to determine if there was significant 
overlap in the genes that are mutated in mouse and human AML, as well as if there 
was significant overlap in the protein domains that are affected in genes mutated in 
both mouse and human AML.  The significance of recurrently mutated protein 
domains was tested using the binomial test, where p = length of domain (in AA) / 
length of protein (in AA).  To determine if mouse leukemias were significantly 
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different from human leukemias with respect to the frequency with which all protein 
classes were affected by gene mutations, protein classes annotated using PANTHER185 
were compared across the two groups using the Pillai-Bartlett statistic from a 
multivariate analysis of variance (MANOVA) model. The corresponding p-values 
were computed from a transformed value of the test statistic which has an approximate 
F distribution. All calculations were done using R version 3.0 (www.r-project.org). 
 
Flow Cytometry 
 
To determine the immunophenotype of normal and leukemic populations, cells were 
stained with a panel of antibodies against lineage markers, each of which was 
conjugated to APC-Cy7:  CD3, CD4, CD11b, CD19, CD45R, Gr-1, NK1.1, and 
TER119.  Cells were also stained with anti-CD117 (c-KIT) and anti-SCA-1, 
conjugated to PE and PE-Cy7 respectively (BioLegend).  Stained cells were analyzed 
using an LSR Fortessa or LSR II flow cytometer (BD), and data were analyzed using 
FlowJo software.  
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